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High Ro52 Expression in Spontaneous and
UV-Induced Cutaneous Inflammation
Vilija Oke1, Ismini Vassilaki2, Alexander Espinosa1, Linn Strandberg1, Vijay K. Kuchroo3, Filippa Nyberg4,5
and Marie Wahren-Herlenius1
Ro52 is an E3 ubiquitin ligase with a recently identified regulatory role in inflammation. The protein is targeted by
autoantibodies in rheumatic diseases, and Ro52 autoantibodies are specifically associated with cutaneous lupus
erythematosus (CLE) and photosensitivity. The aim of this study was to investigate cutaneous Ro52 expression in CLE
patients and to examine whether UVR might modulate Ro52. Ro52 expression was assessed by immunohistochem-
istry in biopsies derived from CLE lesions (n¼ 25), nonlesional (n¼ 7), and healthy control skin using four anti-Ro52
mAbs generated by us. Ro52 expression was also analyzed in psoriatic, lichenoid, and eczematous lesions. It was
increased in the epidermis of spontaneous CLE lesions as compared with unaffected skin of patients and healthy
controls. High epidermal Ro52 expression was also observed in other inflammatory dermatoses investigated. Ro52
was upregulated in experimentally photoprovoked CLE lesions as observed by immunohistochemistry in sequential
biopsies, which was confirmed in vitro both at the mRNA and protein levels by exposing cultured patient-derived
primary keratinocytes to UVR. In conclusion, Ro52 expression is upregulated in keratinocytes in inflammatory skin
conditions and in response to UVR. High Ro52 expression might lead to the breaking of tolerance and the
generation of Ro52 autoantibodies in genetically susceptible subjects. Further, the upregulation of Ro52 in
keratinocytes after sun exposure might also be a triggering factor for skin lesions in patients with Ro52 antibodies.
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INTRODUCTION
Autoantibodies to Ro52 are often present in patients
diagnosed with lupus, and are associated with photosensi-
tivity and the development of subacute cutaneous lupus
erythematosus (CLE) (Sontheimer et al., 1982). The target for
these autoantibodies is a 52-kDa intracellular protein, which
was recently identified as a RING-dependent E3 ubiquitin
ligase (Espinosa et al., 2006). Patients with systemic lupus
erythematosus (SLE) were shown to have increased levels of
Ro52 in their peripheral blood mononuclear cells, and the
overexpression of Ro52 in a B-cell line showed that Ro52
functionally has both anti-proliferative and cell death-
sensitizing properties (Espinosa et al., 2006). Recent reports
further suggest that Ro52 might have a more general
regulatory role in inflammation and target IRF3 and IRF8 for
degradation (Kong et al., 2007; Higgs et al., 2008).
Skin lesions and photosensitivity are included in the
diagnostic criteria for SLE (Tan et al., 1982). It is well known
that lupus skin lesions or even a flare of systemic disease can
be induced by an exposure to UVR (Lin et al., 2007), and that
UVR induces cytokine release and apoptosis in the skin
(Hawk 1999; Lee and Sinha, 2006; Barkauskaite et al., 2007).
Earlier studies aiming to define the expression of the Ro52
autoantigen in the normal skin and CLE have used mono-
specific patient sera (Lee et al., 1985; Ioannides et al., 2000).
However, anti-Ro52 monoclonal Abs for use in immunohis-
tochemistry (IHC) have not been available. Considering the
risk of contaminating antibodies in the so-called monospe-
cific sera, and the risk of losing high-affinity Abs in affinity
purification procedures, we generated a panel of mAbs to
different domains of Ro52 (Strandberg et al., 2008). These
mAbs were characterized by western blot and ELISA using
cell lysates and recombinant Ro52 protein, respectively, and
were used to investigate the Ro52 expression levels and sub-
cellular localization in the skin of CLE patients and the
influence of UVR on Ro52 protein expression. In this study,
we show that four anti-Ro52 mAbs are suitable tools for
antigen detection by IHC. Using these Ro52 mAbs, we show
that Ro52 is highly expressed in spontaneous and experi-
mentally UV-induced CLE lesions in comparison with the
unaffected skin of CLE patients and healthy controls. The
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upregulation of Ro52 by UVR was confirmed in vitro in
primary patient-derived keratinocyte cultures at both the
mRNA and protein levels.
RESULTS
A panel of four anti-human Ro52 mAbs specifically binds Ro52
To investigate the expression of Ro52 in the skin, we
generated a panel of Ro52 mAbs producing hybridoma
(Strandberg et al., 2008). Purified Abs from four clones
(7.12E11, 7.3D10, 7.8C7, and 7.5F5; Figure 1a) bound a 52-
kDa band in HeLa cell extracts (Figure 1b), and to Ro52 in
ELISA using recombinant purified Ro52 protein (Figure 1c).
The Ro52 mAbs generated staining in the sections of paraffin-
embedded skin, which was abolished by pre-incubating the
mAb with Ro52 (Figure 1d). A parallel analysis in ELISA
verified the loss of Ro52 binding activity after the pre-
incubation (Figure 1e). These experiments show that the
generated mAbs are specific for Ro52, and can be used for
specific detection of the protein in IHC.
Detection of Ro52 in differently fixed human skin specimens by
a panel of four mAbs
The four Ro52 mAbs that bound different epitopes in different
domains of Ro52 (Figure 1a; Strandberg et al., 2008) were
used in IHC. To validate the IHC staining and also in
view of the possibility that the domains of Ro52 are
differentially expressed or modified in inflammation,
we first examined the staining with all four Ro52 mAbs in
seven patients where both frozen and paraffin-embedded
biopsies from their spontaneous CLE lesions and biopsies
from the nonlesional skin were available. All four Ro52
mAbs gave the same staining pattern in nonlesional skin with
weak but predominantly nuclear staining of the epidermis
(Figure 2), whereas Ro52 was strikingly upregulated and
present in both the nucleus and the cytoplasm of the
epidermis in CLE lesions (Figure 2). The upregulation was
most apparent in the cell layers closest to the basal
membrane, and similar staining was obtained in both fresh-
frozen and formaldehyde-fixed paraffin-embedded skin sec-
tions and was detected by all four mAbs (Figure 2). Ro52
expression was also observed in endothelial cells and in
the dermal infiltrates in CLE lesions. Staining with isotype-
matched control Abs (IgG1 and IgG2a) was negative (data not
shown).
As formaldehyde fixation allows better preservation of
tissue and cellular structure and the generated mAbs retained
binding in so treated specimens, sections from paraffin-
embedded biopsies were used in the continued analysis and
one of the Ro52 mAbs, 7.8C7, was chosen for staining of the
whole cohort.
Epidermal cells expressing Ro52 are increased in CLE lesions
Ro52 expression in the epidermis was systematically
scored in CLE lesions, nonlesional skin from CLE patients,
and skin from healthy controls (Figure 3). Ro52 was
upregulated in epidermal cells of CLE lesions. The staining
was especially prominent in the cell layers closest to the
basal membrane and in the follicular epithelium. More than
two-thirds of epidermal cells expressed Ro52 in CLE
lesions (Figure 3b), which was significantly more than in
the unaffected skin of CLE patients (Po0.05) and in
healthy controls (Po0.05) (Figure 3b). In the epidermis of
healthy controls and uninvolved skin of CLE patients,
around half of the cells stained positive for Ro52, with no
significant difference between the groups. In the dermis of
CLE lesions, more than 80% of infiltrating cells were positive
for Ro52.
We next analyzed the subcellular localization of Ro52. In
healthy and nonlesional skin, Ro52 was predominantly
localized to the nucleus (Figure 3a), with weak cytoplasmic
expression. A clearly visible and significant cytoplasmic
upregulation occurred in CLE lesions (Po0.005) (Figures 3a
and b).
The increased cell numbers positive for Ro52 and
increased cytoplasmic expression were observed in both
subacute and chronic CLE lesions, and did not differ between
these two groups (P40.05). High Ro52 expression did not
correlate with the presence of anti-Ro/SSA autoantibodies
(Figure 4a and data not shown). Similarly, high epidermal
Ro52 expression was observed in inflammatory lesions
of psoriasis, lichen planus, and atopic eczema patients
(Figure 4b).
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Figure 1. Specificity of anti-Ro52 monoclonal antibodies. (a) Schematic
representation of the Ro52 protein and domains. Arrows indicate the position
of epitopes bound by Ro52 mAbs used in this study. Binding of Ro52 mAbs to
Ro52 was shown by (b) western blot using HeLa cell extract and (c) ELISA
using recombinant protein. (d) Immunohistochemistry of a CLE lesion using
Ro52 mAb 7.8C7 pre-incubated either with PBS or purified Ro52 full-length
protein. Bar¼ 50 mm. (e) Binding in ELISA to Ro52 of mAb 7.8C7 pre-
incubated either with PBS or purified Ro52 full-length protein.
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UV irradiation induces Ro52 expression in vivo and in vitro
Photosensitivity is a common feature in CLE, and to
investigate whether UV irradiation could induce the Ro52
expression, we used sequential biopsies obtained from
experimentally, UV-induced lesions in four CLE patients
and photoprovoked skin of two healthy individuals. IHC
revealed that in CLE lesions provoked by UVA or UVB, Ro52
was upregulated in the skin in a similar pattern as in
spontaneous lesions: Ro52 protein expression was increased
in the cytoplasm, and most prominent in the basal cell layers
(Figure 5, right column). In healthy individuals, UV photo-
provocation did not induce similar upregulation of Ro52 in
the epidermis (Figure 5, left column).
To experimentally confirm that UV irradiation induced
Ro52 expression, we established primary cultures of kerati-
nocytes obtained from nonlesional skin of CLE patients or
healthy controls. Keratinocytes cultured on glass slides to a
confluence of 70–80% were exposed to 50mJ cm2 of UVR.
UVR visibly upregulated cytoplasmic Ro52, as detected by
immunofluorescence after photoprovocation in keratinocytes
both from CLE patients and healthy controls (Figure 6a), and
was confirmed by quantitative PCR (Figure 6b).
DISCUSSION
Anti-Ro52 autoantibodies are associated with photosensitiv-
ity and the development of subacute CLE, but the expression
Unaffected CLE lesion
Patient 7 Patient 17Patient 1
7.3D10
7.5F5
7.8C7
7.12E11
Paraffin embedded Fresh frozen
Figure 2. Immunohistochemistry of sequential sections from skin biopsies either formalin-fixed and paraffin-embedded (left and middle columns) or
snap-frozen, cryosectioned, and fixed by acetone (right column). Sections were stained with four Ro52 mAbs (7.3D10, 7.5F5, 7.8C7, and 7.12E11) binding
different epitopes of Ro52. The four mAbs generated similar staining patterns in both lesional (middle and right columns) and unaffected (left column) skin in
frozen and paraffin-embedded tissue. Bar¼ 50 mm.
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of this autoantigen in the autoimmunity target organs is not
well known. In this study, we used a panel of anti-Ro52 mAbs
(Strandberg et al., 2008) for assessment of Ro52 expression in
the skin of CLE patients and healthy individuals. The four
Ro52 mAbs binding different epitopes of the protein in the
zinc-finger domain (aa 55–91, mAb 7.12E11) and the coiled-
coil region (aa 176–196, mAb 7.3D10; aa 200–239, mAb
7.8C7; and aa 239–292, mAb 7.5F5) were tested for their
binding in IHC to fresh frozen and paraffin-embedded human
skin tissues. All Ro52 mAbs gave similar staining patterns in
both fixation methods, and the clone 7.8C7 was used for
continued investigations.
Ro52 is a ubiquitously expressed protein (Reymond et al.,
2001). We found that Ro52 was upregulated in the epidermis
of both UV-induced and spontaneous CLE lesions, as well as
in other inflammatory skin conditions, and that Ro52 was
significantly less expressed in the skin of healthy individuals
both before and after photoprovocation. In all CLE lesions,
Ro52 upregulation occurred in the keratinocyte cytoplasm.
This is in contrast to an earlier study where patients’ sera were
used to detect Ro52, and Ro52 was found in the epidermal
cell nuclei of CLE lesions (Ioannides et al., 2000). Although
we detected Ro52 in the nucleus in sectioned tissue, Ro52
localization to the nucleus was absent or scarce in cultured
Healthy control SCLE
Patient control
Epidermal cells
*
100
80
60
40
20
0
Patient control
CLE lesion Healthy control
Patient control
CLE lesion Healthy control
Cytoplasm
**
Subcellular distribution
in epidermal cells
100
80
60
40
20
0
Pe
rc
e
n
ta
ge
 o
f R
o5
2-
po
sit
ive
NucleiPe
rc
e
n
ta
ge
 o
f R
o5
2-
po
sit
ive
DLE
Figure 3. Ro52 expression in healthy controls (n¼ 4), unaffected skin of patients (n¼ 7), and spontaneous CLE lesions (n¼ 25). (a) The Ro52 expression pattern
in nonlesional skin of patients was similar to that of healthy controls. In the epidermis, Ro52 was predominantly localized in keratinocyte nuclei (arrowheads)
and was weakly expressed in the cytoplasm. In CLE lesions (SCLE, n¼ 14, DLE, n¼ 11), Ro52 expression increased in epidermal cells, most apparently in the
cytoplasm (arrows). In the dermis, the infiltrating mononuclear cells were strong Ro52 expressers. Bar¼50 mm. (b) A semiquantitative analysis of Ro52
expression. The numbers of positive cells were higher in the epidermis of CLE lesions than in control skin of patients or healthy individuals (left panel). An
analysis of subcellular localization of Ro52 showed significantly increased levels of cytoplasmic Ro52 in the epidermis of lesional skin (right panel). *Po0.05;
**Po0.005.
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primary cells, as described earlier (Yell et al., 1996). This
might be because of differences in cellular environments and
intercellular signaling, or related to cell-cycle stage and
proliferation.
Basal keratinocytes are the primary focus of injury in CLE,
and interestingly in most of the lesions, a band-like prominent
cytoplasmic staining was observed in this zone. As observed
in the longitudinally followed experimentally UVR-induced
lesions, Ro52 expression coincided with the inflammatory
activity of the lesion: Ro52 expression was low in non-
inflamed skin, high in active, and low in the healing lesions.
UV-mediated Ro52 induction was confirmed by a keratino-
cyte culture in vitro. At 6 hours after UV exposure, Ro52
upregulation was observed in the keratinocyte cytoplasm,
and the induction lasted at least 24 hours, which was further
verified at the mRNA level.
Ro52 is upregulated by several pro-inflammatory stimuli,
including type I and II IFNs in HeLa cells (Zhuang et al.,
1999; Rhodes et al., 2002; Saegusa et al., 2002; Strandberg
et al., 2008). It has further been shown that the stimulation of
keratinocytes with NO or H2O2 results in Ro52 accumulation
in cell nuclei, although some studies suggested that UVR
induces Ro52 translocation to the membrane (Saegusa et al.,
2002; Espinosa et al., 2006; Nobuhara et al., 2007). In this
study, we show that an exogenous factor, UVR, can induce
upregulation of Ro52 in the keratinocyte, a cell targeted by
autoimmunity in lupus erythematosus. Skin exposure to UVR
induces oxidative stress and the release of reactive oxygen
+Ro/SSA –Ro/SSA
Lichen planus Psoriasis Atopic eczema
Figure 4. Ro52 expression in anti-Ro52-positive and anti-Ro52-negative CLE, and in lichen planus, psoriasis, and atopic eczema. (a) Similar high Ro52
expression was found both in patients with (n¼ 20, left column) and without (n¼ 8, right column) anti-Ro/SSA autoantibodies. (b) Ro52 expression in the
epidermis and cells infiltrating the dermis in lichen planus, psoriasis, and atopic eczema. Bar¼50 mm.
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species, such as H2O2 or NO (Kulms and Schwarz, 2002),
which may thus mediate the UV-induced upregulation of
Ro52. As we observed similarly strong Ro52 expression in
spontaneous and UV-induced lesions, we suggest that in vivo
a combination of pro-inflammatory cytokines and oxidative
stress may contribute to the observed Ro52 upregulation.
The similar high Ro52 expression in the anti-Ro52-positive
and anti-Ro52-negative CLE lesions and other inflammatory
skin diseases in our study suggests that the development of
Ro52 autoantibodies is not only dependent on the high Ro52
protein expression levels. Other earlier identified factors
influencing the generation of Ro52 Abs is HLA (human
leukocyte antigen), where HLA-A1-B8-DR3 is associated
with Ro52 autoantibodies (Ricchiuti et al., 1994). The genetic
background of the individual may thus determine whether
Ro52 Abs develop in response to high Ro52 protein
expression during inflammation.
High Ro52 expression is associated with decreased cell
proliferation and apoptosis induction (Espinosa et al., 2006;
Strandberg et al., 2008). Apoptotic cell accumulation occurs
in both spontaneous and UVR-induced CLE lesions (Kuhn
et al., 2006), and clearance of these cells is impaired in
patients with SLE (Gaipl et al, 2007). Apoptotic cell
opsonization with Ro/SSA-positive sera might rather prevent
than facilitate phagocytosis (Reefman et al., 2007). It has also
been reported that Ro52 itself may bind the Fc portion of
Healthy control CLE patient
UVB UVB UVA
4 days
7 days
14 days
30 days
Figure 5. Expression of Ro52 in UV-photoprovoked skin of a healthy individual and a CLE patient. UV exposure induced minimal upregulation of Ro52 in
the epidermis of healthy individuals; the endothelia and scattered cells in the dermis remain mainly negative (left column). Ro52 expression in active
UV-induced CLE lesions increased, with strong cytoplasmic staining of keratinocytes. As lesions healed, Ro52 was downregulated (right column). Bar¼ 50 mm.
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circulating IgG (Rhodes and Trowsdale, 2007; Takahata
et al., 2008), which might further block opsonization
and clearance of cell debris. Increased and inefficient
apoptosis may also lead to secondary necrosis, which is an
inflammatory process (Gaipl et al., 2007). Cytokine release
induced by UVR per se and because of secondary keratino-
cyte necrosis might thereafter lead to a strong inflammatory
response.
Mononuclear cell accumulation is a typical histopatholo-
gical feature of CLE (David-Bajar and Davis, 1997). Dermal
antigen-presenting cells express B7-1 and B7-2 receptors, and
infiltrating T cells, which predominately are CD4þ cells,
possess CD28 molecules (Denfeld et al., 1997). Our study
showed that the majority of infiltrating dermal cells expresses
Ro52. Overexpression of Ro52 in T cells is associated with
cell activation and IL-2 secretion (Ishii et al., 2003), which in
the CLE lesions might lead to further promotion of the dermal
inflammation.
In conclusion, Ro52 is upregulated in CLE and in other
inflammatory dermatoses, which suggests its biological role
in inflammation of the skin. Ro52 is induced by UVR—an
exogenous pro-inflammatory stimulus that also triggers CLE
lesions. In CLE patients, the induction of Ro52 might be
associated with an increased rate of keratinocyte apoptosis
and impaired phagocytosis, with increased antigenic load,
breakage of tolerance, and development of autoimmunity.
MATERIALS AND METHODS
Patients and skin samples
Skin punch biopsies (3–4mm) from spontaneous CLE lesions were
obtained from 25 patients, and biopsies of unaffected buttock skin were
obtained from 7 of these patients. Serial biopsies from experimentally,
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UV-induced LE lesions of four additional patients and two healthy
individuals who participated in a photoprovocation study described
elsewhere (Nyberg et al., 1998; Barkauskaite et al., 2007), were also
analyzed. CLE was classified by clinical and histopathological findings
according to the Gilliam classification (David-Bajar and Davis, 1997;
Kuhn et al., 2001). Eleven of the patients also fulfilled criteria for SLE
(Tan et al., 1982). Skin biopsies of four healthy volunteers served as
normal skin controls. Additional skin biopsies from unaffected skin of
five CLE patients and two healthy controls were used to generate
keratinocyte cultures. Clinical data of the CLE patients are shown in
Table 1. Skin biopsies of lesions from lichen planus (n¼ 1), psoriasis
(n¼ 1), and atopic eczema (n¼ 3) were included in the study. All
participants gave informed consent and the study was approved by the
Regional Human Ethics committee at the Karolinska University
Hospital. In some cases, skin biopsies had been acquired before
Swedish Biobank Laws required written informed consent. In all such
cases, the consent was acquired orally and noted in patient’s medical
documentation. The study was conducted according to the Declaration
of Helsinki Principles.
Ro52 mAbs
mAbs against human Ro52 were generated by standard hybridoma
protocols as described (Strandberg et al., 2008). Briefly, BALB/c mice
were immunized and boosted with purified and refolded recombi-
nant His-tagged human Ro52 full-length protein. An anti-Ro52 Ab
titer increase was monitored by ELISA. Mice were killed 4 days after
the last boost, and spleens collected for preparation of single cell
suspension. Spleen cells were fused with SP 2/0 myeloma cells and
hybridoma grown in 96-well plates. After 2 weeks, supernatants
were screened for Ro52 IgG Abs in ELISA, and positive clones were
subcloned at least twice by limiting dilution.
IgG from supernatants of hybridoma 7.3D10 (IgG2a), 7.5F5
(IgG2a), 7.8C7 (IgG1), and 7.12E11 (IgG1) (Strandberg et al., 2008)
were purified by protein-A/protein-G beads and used in this study.
Western blot
The extracts of HeLa cells were denaturated by boiling 5minutes in
5% SDS sample buffer, separated by 10% SDS-PAGE gels and
transferred to a nitrocellulose membrane. The membrane was
blocked with 5% (w/v) fat-free milk 0.1% Tween 20-phosphate-
buffered saline (PBS) (TPBS) overnight at þ 4 1C. Thereafter, filters
were incubated with either mouse mAbs or Ro52-positive patient
sera (1:500) at room temperature (RT) for 2 hour, followed by
incubation with horseradish peroxidase-conjugated rabbit anti-
mouse IgG (1:2,000, DakoCytomation, Glostrup, Denmark) or rabbit
anti-human IgG (1:1,000, DakoCytomation) in RT for 1 hour. All Abs
were diluted in 5% (w/v) fat-free milk in TPBS, and the membranes
were washed in TPBS between incubations. Blots were developed
with the ECL system (Amersham Biosciences, Little Chalfont, UK).
ELISA
ELISA was performed as described earlier (Salomonsson et al.,
2002a). In short, high-binding 96-well plates (Nunc, Odenno,
Denmark) were coated with purified full-length Ro52 expressed
from the pMAL-vector (New England Biolabs, Beverly, MA) or with
wild-type vector encoded maltose-binding protein as control. The
plates were coated overnight with 1mg protein per well, diluted in
carbonate buffer, pH 9.6. Plates were blocked with 5% (w/v) fat-free
Table 1. Characterization of patients and healthy
individuals in the study
No.
Sex/age
(years) Diagnosis1
CLE
subtype Anti-Ro/SSA2
Anti-La/
SSB
1 F/63 CCLE DLE  
2 M/62 CCLE DLE  
3 M/76 SCLE SCLE + +
4 M/52 SLE SCLE + +
5 F/26 SLE DLE + 
6 F/56 CCLE DLE  
7 F/67 SLE SCLE + +
8 F/35 SLE SCLE + (Ro52) +
9 F/37 CCLE DLE + 
103 F/79 SCLE SCLE + 
11 F/32 SLE SCLE + 
12 F/55 CCLE DLE  
13 F/33 SLE SCLE + (Ro52, Ro60) +
14 F/55 SCLE SCLE + 
15 M/50 SCLE SCLE  
16 M/53 SLE SCLE + 
17 F/65 SLE SCLE + 
18 F/78 SCLE SCLE + 
19 F/44 CCLE DLE  
203 M/73 CCLE DLE + 
21 F/39 CCLE DLE  
22 F/37 SLE DLE + (Ro60) 
23 F/81 CCLE DLE  
24 F/60 SCLE SCLE + 
25 F/64 SCLE SCLE + 
263 F/68 CCLE DLE + 
273 M/32 SLE SCLE + 
283 F/51 CCLE DLE + +
HC1 F/44
HC2 F/54
HC3 F/62
HC4 F/45
HC53 M/26
HC63 F/28
CLE, cutaneous lupus erythematosus; DLE, discoid lupus erythematosus;
F, female; M, male; SCLE, sub-acute cutaneous lupus erythematosus.
1Medication of the patients during the acquisition of skin biopsies: patient
nos. 4, 5, 7, 10, 11, 21, and 25 were treated with p5mg of prednisone.
Patient nos. 4, 5, 22, 24, and 25 received antimalarials, and patient no 5,
11, 21 and 24 received other disease-modifying antirheumatic drugs.
Patient no. 18 developed SCLE after treatment of a hepatocellular
carcinoma by IFN-a.
2When data were available, a distinction of whether the patient had anti-
Ro52 and/or anti-Ro60 is given.
3Patients and controls whose biopsies were used for derivation of
keratinocyte cultures.
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milk in TPBS for 30minutes, washed and incubated with Ro52 mAb
or patient sera, diluted at 2 mgml1 and 1:2,000 in duplicates for
60minutes. After washing, bound Abs were detected by affinity-
purified alkaline phosphatase-conjugated rabbit anti-mouse IgG or
rabbit anti-human IgG (DakoCytomation), both diluted at 1:2,000.
Samples were developed with phosphatase substrate (Sigma, St
Louis, MO), dissolved in diethanolamine buffer (pH 9.6), and the
absorbance was measured at 405 nm. All steps were performed at RT
except coating, which was performed at þ 4 1C.
In pre-incubation experiments, mAbs were incubated with full-
length purified Ro52 (Salomonsson et al., 2002b) (Ab–protein (w/w)
at ratio 1:40) overnight at 4 1C in PBS. The mix was then diluted to
reach an Ab concentration of 2 mgml1 and used in ELISA and IHC.
IHC
Biopsies were fixed in 4% paraformaldehyde, paraffin-embedded,
and kept at RT until sectioning. Some biopsies were divided in half
before paraformaldehyde fixation, and one half was snap-frozen and
kept at 70 1C until sectioning.
Frozen biopsies were sectioned (7 mm) in a cryostat. The sections
were placed on chrome gelatin-coated slides and air-dried for
30minutes before fixation in ice-cold 50% acetone for 30 seconds,
followed by 3minutes in 100% acetone, and thereafter air-dried.
From paraformaldehyde-fixed, paraffin-embedded biopsy speci-
mens, 8mm sections were cut in a microtome and placed on
positively charged glass slides. The sections were deparaffinized by
heating at þ 60 1C for 18 hours, incubated in xylene twice for
5minutes, and rehydrated by immersing for 5minutes into gradually
diluted ethanol solutions (99, 95, and 70%), and thereafter washed
in PBS. Antigen retrieval was performed by heating the slides in
citrate solution (pH 6) at 98 1C for 40minutes, thereafter allowing
slides to cool, and washing in water for 10minutes. After these steps,
the same immunohistochemical staining protocol was used for both
paraffin-embedded and frozen tissue sections, except that the PBS
solution for the paraformaldehyde-fixed slides contained 0.01%
saponine throughout the procedure to permeabilize cells.
The full IHC procedure has been described earlier (Barkauskaite
et al., 2007). In brief, slides were washed and then consecutively
treated with 1% hydrogen peroxide for 30minutes in the dark, avidin
and biotin blocking solutions (Vector, Burlingame, CA), and 2%
normal horse serum for 20minutes. Washing in PBS was performed
between each step. Primary Ab (Ro52 mouse monoclonal 7.3D10
(2mgml1), 7.5F5 (5.6 mgml1), 7.8C7 (2mgml1), and 7.12E11
(3.3 mgml1) (Strandberg et al., 2008)) or corresponding amount of
isotype control (mouse IgG1 or IgG2a; DakoCytomation) was added
to the sections and incubated at RT for 60minutes in a humidified
chamber. After rinsing, biotinylated horse anti-mouse IgG (2 mgml1,
Vector) in PBS with 2% normal horse serum was added to sections
and incubated for 60minutes. The slides were then washed and
treated with a pre-formed complex of biotin and peroxidase-labeled
avidin (DakoCytomation) for 45minutes and then developed with
the diaminobenzidine kit (Vector) shielded from light for 10minutes.
Slides were counterstained with Mayer’s hematoxylin and mounted
under coverslips using Mountex (HistoLab, Gothenburg, Sweden).
Keratinocyte culture and UVR provocation in vitro
A Waldman UV200 lamp (Villingen-Schwenningen, Germany),
provided with TL12 bulbs with emission spectrum of 290–320 nm
and 2.0mWcm2 irradiance at the cell surface, was used as source
for UV. UV doses were measured with a Waldman UV meter (type
585 100).
To establish keratinocyte cultures, skin biopsies were washed in
PBS immediately after acquisition, and thereafter in 0.004%
gentamycin/PBS (Gibco/Invitrogen, Carlsbad, CA) six times and
incubated in 5Uml1 dispase (Gibco/Invitrogen) at 4 1C overnight.
Keratinocytes were then extracted by lifting the epidermis and
squeezing gently, and cultured in the serum-free keratinocyte culture
medium (Gibco/Invitrogen) with the addition of bovine pituitary
extract (2.16mgml1) and epidermal growth factor (0.2 mgml1).
The keratinocyte cultures were expanded in three passages and
thereafter stored in liquid nitrogen until use.
Before experiments, cells were passaged once and then seeded
on slides or culture dishes. After 2–3 days, when reaching 70–80%
confluence, cells were exposed to UVR. The UVR doses tested
ranged between 10 and 60mJ cm2. UVR doses lower than
30mJ cm2 did not induce any changes of Ro52 expression, and
doses higher than 60mJ cm2 were lethal. Therefore, keratinocytes
were exposed to 50mJ cm2 UVR in all experiments.
At 6 or 24 hours after UV exposure, keratinocytes were
washed with ice-cold PBS and either fixed by 4% paraformaldehyde
and used for immunocytochemistry or harvested for RNA
extraction.
Immunofluorescence
Immunofluorescence staining was performed as described earlier
(Strandberg et al., 2008). Briefly, cultured and fixed cells were
permeabilized by 0.2% Triton X-100 (Sigma, Munich, Germany) and
then stained with Ro52 mAbs (5 mgml1) in 0.02% Triton X-100.
Alexa-594-conjugated donkey anti-mouse (5mgml1; Invitrogen,
Carlsbad, CA) was used as a secondary Ab. Slides were mounted
with a ProLong Gold anti-fade reagent (Invitrogen).
Quantitative reverse transcription-PCR of Ro52
Quantitative reverse transcription-PCR for Ro52 was performed as
described in detail earlier (Espinosa et al., 2006). Briefly, total RNA
was isolated from cultured keratinocytes using the RNeasy Mini Kit
with on-column RNase-free DNAse digestion (Qiagen, Germany),
and was reverse-transcribed to cDNA using random hexamers,
0.5mM dNTP, 40U of RNaseOUT, and 200U superscript (Invitro-
gen). PCR was performed with an iQ5 system (Bio-Rad, Richmond,
VA) using a SYBR Green PCR Kit (Qiagen) with the primers: Ro52-F,
50-GAACTGCTGCAGGAGGTGATAA-30 and Ro52-R, 50-AGTTCTG
GAGAGGTAATATCCAGGTC-30; GAPDH-F, 50-AGGGCTGCTTT
TAACTCTGGTAAA-30 and GAPDH-R, 50-CATATTGGAACATGT
AAACCATGTAGTTG-30, using a three-step protocol (95 1C for
10minutes, followed by 95 1C for 15 seconds, 65 1C for 30 seconds,
and 72 1C for 40 cycles). The amplification was performed in 96-well
plates in doublets and a standard curve was constructed using five-
fold serial dilutions of pooled cDNA from five samples. The
expression level of Ro52 in each sample was calculated as the ratio
between the relative amount of Ro52 mRNA and the relative amount
of GAPDH mRNA.
Evaluation of staining
The stained slides were analyzed in a Polyvar II light microscope
(Reichert-Jung, Vienna, Austria) and a Leica DMRXA2 fluorescence
2008 Journal of Investigative Dermatology (2009), Volume 129
V Oke et al.
Ro52 Induction and Expression in Lupus Lesions
microscope provided with a Q500IW camera (UK). The evaluation
of Ro52-positive cells in the epidermis was performed by counting
all stained cells out of all present cells in each section. The
percentage of cells with nuclear and/or cytoplasmic Ro52 was
determined by relating number of cells positive for nuclear and
cytoplasmic staining, respectively, to the total number of cells in the
epidermis in the section. The mean values of three investigated areas
were calculated and used for statistical analysis. Dermal infiltration
was assessed as the percentage of area evaluating a representative
3mm2 area. Ro52 staining in the dermis was evaluated in
three randomly chosen infiltrated areas, and expressed as the
percentage of positive cells/present cells. Biopsies were coded,
assessed, and scored in a blinded manner by VO and FN.
Differences in scores were evaluated and solved in conference with
a dermatopathologist.
Statistical analysis
A nonparametric Wilcoxon test for comparison of matched pairs and
the Kruskal–Wallis test for independent samples were used for
statistical analysis with Statistica and GraphPad software. P-values
o0.05 were considered significant.
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